Table 3.
Reported treatment characteristics, adverse events and system failures per reported treatments
| Overall (n = 102) | Survivor (n = 58) | Non-survivor (n = 44) | |
|---|---|---|---|
| Seraph treatment time (h) | |||
| n | 102 | 58 | 44 |
| Median (Q1, Q3) | 5.00 (4.00, 13.4) | 4.17 (4.00, 5.23) | 6.00 (4.21, 23.5) |
| Treated blood volume (L) | |||
| n | 64 | 32 | 32 |
| Median (Q1, Q3) | 71.3 (43.7, 109) | 66.8 (48.0, 84.0) | 76.9 (8.53, 158) |
| Missing (%) | 38 (37.3) | 26 (44.8) | 12 (27.3) |
| Seraph as standalone treatment | |||
| No (%) | 55 (53.9) | 30 (51.7) | 25 (56.8) |
| Yes (%) | 44 (43.1) | 26 (44.8) | 18 (40.9) |
| Missing (%) | 3 (2.9) | 2 (3.4) | 1 (2.3) |
| Adverse event | |||
| No (%) | 83 (81.4) | 49 (84.5) | 34 (77.3) |
| Yes (%) | 9 (8.8) | 6 (10.3) | 3 (6.8) |
| Missing (%) | 10 (9.8) | 3 (5.2) | 7 (15.9) |
| Vascular access | |||
| Double lumen catheter (%) | 62 (60.8) | 30 (51.7) | 32 (72.7) |
| Shunt/AV fistula (%) | 7 (6.9) | 5 (8.6) | 2 (4.5) |
| ECMO circuit (%) | 1 (1.0) | 0 (0) | 1 (2.3) |
| Missing (%) | 32 (31.4) | 23 (39.7) | 9 (20.5) |
| Hours | |||
| n | 64 | 32 | 32 |
| Median (Q1, Q3) | 5.50 (4.00, 24.0) | 4.00 (4.00, 10.0) | 16.8 (4.00, 24.0) |
| Missing (%) | 38 (37.3) | 26 (44.8) | 12 (27.3) |
| Anticoagulation | |||
| Citrate (%) | 15 (14.7) | 3 (5.2) | 12 (27.3) |
| Heparin (%) | 66 (64.7) | 41 (70.7) | 25 (56.8) |
| Other (%) | 8 (7.8) | 6 (10.3) | 2 (4.5) |
| Missing (%) | 13 (12.7) | 8 (13.8) | 5 (11.4) |
| Clotting event | |||
| No (%) | 92 (90.2) | 52 (89.7) | 40 (90.9) |
| Yes (%) | 9 (8.8) | 6 (10.3) | 3 (6.8) |
| Missing (%) | 1 (1.0) | 0 (0) | 1 (2.3) |
AV, vascular access; ECMO, extracorporeal membrane oxygenation.